Search

Your search keyword '"Mencarini, V."' showing total 14 results
Start Over Author "Mencarini, V." Publication Year Range Last 10 years
14 results on '"Mencarini, V."'

1. [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020]

Author

Campagna, G., Amato, A., Majo, F., Ferrari, G., Quattrucci, S., Padoan, R., Floridia, G., Salvatore, D., Carnovale, V., Puppo Fornaro, G., Angiolillo, A., Badolato, R., Battistini, F., Bernardi, M. A., Bertasi, S., Bignamin, I., Caloiero, M., Cannata, L., Carnicella, A., Castellani, C., Ciciretti, M. A., Cimino, G., Cipolli, M., Cirilli, N., Collura, M., Colombo, C., De Venuto, D., Di Sabatino, M, Donati, V., Fabrizi, B., Ficili, F., Francalanci, M., Giordano, P., Iansa, P., Laezza, C., Leonardi, S., Lucanto, M. C., Lucidi, V., Macchiaroli, A. M., Manca, A., Maschio, M., Mascotto, D., Mencarini, V., Messore, B., Moretti, P., Negri, A., Pantano, S., Palladino, N., Pintani, E., Pisano, G., Pisi, G., Pizzamiglio, G., Pradal, U., Raia, V., Redemagni, A., Ripani, P., Ros, M., Rotolo, N., Rottigni, S., Salvatore, M., Scarlata, A., Serio, L., Spaggiari, C., Taccetti, G., Taruscio, D., and Vitullo, P

Subjects
Adult, Male, CF referral centre, Adolescent, Cystic Fibrosis, [delta]F508, COVID-19, FEV, registry, BMI, Young Adult, CF support centre, Italy, cystic fibrosis, Child, Child, Preschool, Female, Humans, Pandemics, Registries, Preschool
Published
2022

2. Italian cystic fibrosis registry (ICFR): Report 2017-2018

Author

Campagna, G., Amato, A., Majo, F., Ferrari, G., Quattrucci, S., Padoan, R., Floridia, G., Salvatore, D., Carnovale, V., Fornaro, G. P., Taruscio, D., Salvatore, M., Angiolillo, A., Baldo, E., Battistini, F., Bernardi, M. A., Bertasi, S., Bignamini, E., Bisogno, A., Braggion, C., Caloiero, M., Cannata, L., Carnicella, A., Cellini, C., Ciciretti, M. A., Cimino, G., Cipolli, M., Cirilli, N., Collura, M., Colombo, C., Sabatino, M. D., Donati, V., Fabrizi, B., Ficili, F., Francalanci, M., Iansa, P., Laezza, C., Leonardi, S., Lucanto, M. C., Lucidi, V., Macchiaroli, A. M., Manca, A., Maschio, M., Mascotto, D., Mencarini, V., Messore, B., Minicucci, L., Moretti, P., Negri, A., Pantano, S., Palladino, N., Pintani, E., Pisano, G., Pisi, G., Pizzamiglio, G., Quattromano, E., Raia, V., Redemagni, A., Ros, M., Rotolo, N., Rottigni, S., Scarlata, A., Spaggiari, C., Taccetti, G., Vassanelli, C., and Vitullo, P.

Subjects
Adult, Male, CF referral centre, Registry, Adolescent, Cystic Fibrosis, [delta]F508, Cystic Fibrosis Transmembrane Conductance Regulator, FEV, BMI, Young Adult, CF support centre, Italy, Cystic fibrosis, Child, Female, Humans, Registries, Lung Transplantation
Published
2021

4. Innesti. Tra progetto di paesaggio e gestione dei rischi territoriali nel paesaggio agrario. Il caso studio di Mezzano all'interno del PAESC di Ravenna

Author

Mencarini, V. and Lobosco, G.

Subjects
landscape design, cambiamento climatico, piano di adattamento, building geography, paesaggi agricoli, climate change, landscape design, agricultural landscape, cambiamento climatico, building geography, Ambientale, adaptation plan, piano di adattamento, landscape design, climate change, adaptation plan, building geography, agricultural landscape, paesaggi agricoli, SH3_9
Published
2021

6. Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016

Author

Giordani, B., Amato, A., Majo, F., Ferrari, G., Quattrucci, S., Minicucci, L., Padoan, R., Floridia, G., Salvatore, D., Carnovale, V., Puppo Fornaro, G., Taruscio, D., Salvatore, M., Albera, C, Amato, A, Angiolillo, A, Baldo, E, Battistini, F, Bena, C, Bernardi, Mg, Bertasi, S, Bignamini, E, Bisogno, A, Braggion, C, Cannata, L, Carnicella, A, Carnovale, V, Ciciretti, Ma, Cipolli, M, Cirilli, N, Colombo, C, Cucchiara, S, Di Sabatino, M, Di Stefano, E, Fabrizi, B, Ferrari, G, Ficili, F, Floridia, G, Francalanci, M, Gagliardini, R, Giordani, B, Iansa, P, Laezza, C, Leonardi, S, Lucanto, Mc, Lucidi, V, Macchiaroli, Am, Magazzù, G, Majo, F, Manca, A, Maschio, M, Mascotto, D, Mencarini, V, Minicucci, L, Moretti, P, Negri, A, Padoan, R, Palladino, N, Pintani, E, Pisano, G, Pisi, G, Pizzamiglio, G, Quattrucci, S, Raia, V, Ratclif, L, Ros, M, Rotolo, N, Salvatore, D, Salvatore, M, Spaggiari, C, Taruscio, D, Tonelli, T, Tuccio, G, Vassanelli, C, Vitullo, P, and Zavataro L, .

Published
2019

7. Italian Cystic Fibrosis Registry. Report 2011-2014

Author

Barbara, Giordani, Annalisa, Amato, Fabio, Majo, Gianluca, Ferrari, Serena, Quattrucci, Laura, Minicucci, Rita, Padoan, Giovanna, Floridia, Gianna Puppo Fornaro, Domenica, Taruscio, Marco, Salvatore, Gruppo di lavoro RIFC, Albera, C, Amato, A, Angiolillo, A, Assael, Bm, Baldo, E, Battistini, F, Bena, C, Bernardi, Mg, Bertasi, S, Bignamini, E, Bisogno, A, Braggion, C, Cannata, L, Carnicella, A, Carnovale, V, Ciciretti, Ma, Cirilli, N, Collura, M, Colombo, C, Cucchiara, S, Di Sabatino, M, Di Stefano, E, Ferrari, G, Ficili, F, Floridia, G, Francalanci, M, Gagliardini, R, Giordani, B, Iansa, P, Laezza, C, La Rosa, M, Leonardi, S, Lucanto, Mc, Lucidi, V, Macchiaroli, Am, Magazzù, G, Majo, F, Manca, A, Mascotto, D, Mencarini, V, Minicucci, L, Moretti, P, Negri, A, Padoan, R, Palladino, N, Pintani, E, Pisano, G, Pisi, G, Pizzamiglio, G, Poli, F, Quattrucci, S, Raia, V, Ratclif, L, Ros, M, Rotolo, N, Salvatore, D, Salvatore, M, Spaggiari, C, Taruscio, D, Tonelli, T, Tuccio, G, and Zavataro, L.

Subjects
Registry, Cystic Fibrosis, Italy, Cystic Fibrosis, Registry, Italy
Published
2018

9. Italian Cystic Fibrosis Register - Report 2010

Author

Amato, A, Ferrigno, L, Salvatore, M, Toccaceli, V, Gruppo di lavoro RIFC/ICFR Working Group, Albera, C, Assael, B, Baldo, E, Battistini, F, Bena, C, Bernardi, M, Bertasi, S, Bignamini, E, Bisogno, A0, Braggion, C1, Cannata, L, Carnicella, A, Carnovale, V, Ciciretti, M, Cirilli, N, Collura, M, Colombo, C, Contoli, B, Cotichini, R, Cristadoro, S, Cucchiara, S, Ferrari, G, Ficili, F, Fogazza, D, Forte, F, Francalanci, M, Gagliardini, R, Iansa, P, Laezza, C, La Rosa, M, Lucidi, V, Magazzù, G, Majo, F, Manca, A, Mascotto, D, Mencarini, V, Minicucci, L, Moretti, P, Padoan, R, Pintani, E, Pisi, G, Pizzamiglio, G, Poli, F, Quattrucci, S, Raia, V, Ratclif, L, Ros, M, Salvatore, D, Seia, M, Spaggiari, C, Stazi, M, Taruscio, D, Tonelli, T, Tuccio, G, and Zavataro, L

Subjects
Registry, Cystic Fibrosis, Italy, Cystic Fibrosis, Registry, Italy
Published
2016

10. Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society

Author

Carla, Colombo, Marco, Cipolli, Valeria, Daccò, Paola, Medino, 1 Federico Alghisi, 4 Maura Ambroni, 5 Raffaele Badolato, 6 Fiorella Battistini, 5 Elisabetta Bignamini, 7 Rosaria Casciaro, 8 Fabiana Ciciriello, 4 Mirella Collura, 9 Isabella Comello, 10 Michela Francalanci, 11 Francesca Ficili, 9 Anna Folino, Leonardi, Salvatore, 12 Giuseppina Leonetti, 13 Maria Cristina Lucanto, 14 Francesca Lucca, 3 Massimo Maschio, 15 Valeria Mencarini, 16 Barbara Messore, 17 Giovanna Pisi, 18 Giovanna Pizzamiglio, 19 Piercarlo Poli, 6 Valeria Raia, 20 Luca Riberi, 17 Mirco Ros, 10 Novella Rotolo, 12 Angela Sepe, 20 Giovanni Taccetti, 11 Pamela Vitullo, 21 and Gianfranco Alicandro1, 2, Colombo, C, Cipolli, M, Daccò, V, Medino, P, Alghisi, F, Ambroni, M, Badolato, R, Battistini, F, Bignamini, E, Casciaro, R, Ciciriello, F, Collura, M, Comello, I, Francalanci, M, Ficili, F, Folino, A, Leonardi, S, Leonetti, G, Lucanto, Mc, Lucca, F, Maschio, M, Mencarini, V, Messore, B, Pisi, G, Pizzamiglio, G, Poli, P, Raia, V, Riberi, L, Ros, M, Rotolo, N, Sepe, A, Taccetti, G, Vitullo, P, and Alicandro, G.

Subjects
Microbiology (medical), Original Paper, Pandemic, SARS-CoV-2, COVID-19, General Medicine, Cystic fibrosis, Infectious Diseases, Italy, Risk Factors, Cystic fibrosi, Humans, Exocrine Pancreatic Insufficiency, Prospective Studies
Abstract

Purpose To describe the clinical course of COVID-19 in patients with cystic fibrosis (CF) and to identify risk factors for severe COVID-19. Methods We conducted a prospective study within the Italian CF Society. CF centers collected baseline and follow-up data of patients with virologically confirmed SARS-CoV-2 infection between March 2020 and June 2021. Odds ratios (ORs) for severe SARS-CoV-2 (as defined by hospital admission) were estimated by logistic regression models. Results The study included 236 patients with positive molecular test for SARS-CoV-2. Six patients died, 43 patients were admitted to hospital, 4 admitted to intensive care unit. Pancreatic insufficiency was associated with increased risk of severe COVID-19 (OR 4.04, 95% CI 1.52; 10.8). After adjusting for age and pancreatic insufficiency, forced expiratory volume in one second (FEVp)

Published
2021

11. Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society.

Author

Colombo C, Cipolli M, Daccò V, Medino P, Alghisi F, Ambroni M, Badolato R, Battistini F, Bignamini E, Casciaro R, Ciciriello F, Collura M, Comello I, Francalanci M, Ficili F, Folino A, Leonardi S, Leonetti G, Lucanto MC, Lucca F, Maschio M, Mencarini V, Messore B, Pisi G, Pizzamiglio G, Poli P, Raia V, Riberi L, Ros M, Rotolo N, Sepe A, Taccetti G, Vitullo P, and Alicandro G

Subjects
Humans, Italy epidemiology, Prospective Studies, Risk Factors, SARS-CoV-2, COVID-19 epidemiology, Cystic Fibrosis complications, Exocrine Pancreatic Insufficiency complications
Abstract

Purpose: To describe the clinical course of COVID-19 in patients with cystic fibrosis (CF) and to identify risk factors for severe COVID-19., Methods: We conducted a prospective study within the Italian CF Society. CF centers collected baseline and follow-up data of patients with virologically confirmed SARS-CoV-2 infection between March 2020 and June 2021. Odds ratios (ORs) for severe SARS-CoV-2 (as defined by hospital admission) were estimated by logistic regression models., Results: The study included 236 patients with positive molecular test for SARS-CoV-2. Six patients died, 43 patients were admitted to hospital, 4 admitted to intensive care unit. Pancreatic insufficiency was associated with increased risk of severe COVID-19 (OR 4.04, 95% CI 1.52; 10.8). After adjusting for age and pancreatic insufficiency, forced expiratory volume in one second (FEVp) < 40% (OR 4.54, 95% CI 1.56; 13.2), oxygen therapy (OR 12.3, 95% CI 2.91-51.7), underweight (OR 2.92, 95% CI 1.12; 7.57), organ transplantation (OR 7.31, 95% CI 2.59; 20.7), diabetes (OR 2.67, 95% CI 1.23; 5.80) and liver disease (OR 3.67, 95% CI 1.77; 7.59) were associated with increased risk of severe COVID-19, while use of dornase alfa was associated with a reduced risk (OR 0.34, 95% CI 0.13-0.88). No significant changes were observed in FEVp from baseline to a median follow-up of 2 months (median difference: 0, interquartile range: - 4; 5, P = 0.62)., Conclusion: Clinical features indicative of severe form of CF are associated with increased risk of COVID-19 hospitalization. SARS-CoV-2 infected patients do not experience a deterioration of respiratory function., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)

Published
2022
Full Text
View/download PDF

12. A Peculiar Case of Pneumonia due to Mycoplasma pneumoniae in a Child with Cystic Fibrosis and Sensibilization to Aspergillus fumigatus .

Author

Peccini L, Pennoni S, Mencarini V, Saponara M, Palladino N, Principi N, Pennoni G, and Esposito S

Abstract

Aspergillus fumigatus plays a major role in pulmonary exacerbations in patients with cystic fibrosis. The most common A. fumigatus diseases are those based on immune-mediated response to A. fumigatus antigens; including allergic bronchopulmonary aspergillosis (ABPA). In this condition; the presence of A. fumigatus in the lower respiratory tract triggers an IgE-mediated hypersensitivity response that causes airway inflammation; bronchospasms; and bronchiectasis. This case report describes a ten-year-old male patient suffering from cystic fibrosis (CF) in whom the diagnosis of ABPA occurred in association with pneumonia due to Mycoplasma pneumoniae more than two weeks after hospitalization. This case is a good example of how difficult the identification of ABPA in CF patients can be and highlights that ABPA can occur in association with co-infections due to other pathogens. In order to avoid the risk of a late ABPA diagnosis, it is imperative that the diagnostic criteria guidelines are reviewed and standardized., Competing Interests: The authors declare no conflict of interest.

Published
2019
Full Text
View/download PDF

13. Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis.

Author

Esposito S, Pennoni G, Mencarini V, Palladino N, Peccini L, and Principi N

Abstract

Staphylococcus aureus is a ubiquitous human commensal pathogen. It is commonly isolated in cystic fibrosis (CF) patients and is considered one of the main causes of the recurrent acute pulmonary infections and progressive decline in lung function that characterize this inherited life-threatening multisystem disorder. However, the true role of S. aureus in CF patients is not completely understood. The main aim of this narrative review is to discuss the present knowledge of the role of S. aureus in CF patients. Literature review showed that despite the fact that the availability and use of drugs effective against S. aureus have coincided with a significant improvement in the prognosis of lung disease in CF patients, clearly evidencing the importance of S. aureus therapy, how to use old and new drugs to obtain the maximal effectiveness has not been precisely defined. The most important problem remains that the high frequency with which S. aureus is carried in healthy subjects prevents the differentiation of simple colonization from infection. Moreover, although experts recommend antibiotic administration in CF patients with symptoms and in those with persistent detection of S. aureus , the best antibiotic approach has not been defined. All these problems are complicated by the evidence that the most effective antibiotic against methicillin-resistant S. aureus (MRSA) cannot be used in patients with CF with the same schedules used in patients without CF. Further studies are needed to solve these problems and to assure CF patients the highest level of care.

Published
2019
Full Text
View/download PDF

14. A Clinical and Molecular Survey of 62 Cystic Fibrosis Patients from Umbria (Central Italy) Disclosing a High Frequency (2.4%) of the 2184insA Allele: Implications for Screening.

Author

Prontera P, Isidori I, Mencarini V, Pennoni G, Mencarelli A, Stangoni G, Di Cara G, and Verrotti A

Subjects
Adolescent, Adult, Alleles, Child, Child, Preschool, Cystic Fibrosis diagnosis, Disclosure, Female, Gene Frequency, Genotype, Health Surveys, Humans, Italy, Male, Middle Aged, Mutation, Phenotype, Retrospective Studies, Surveys and Questionnaires, Young Adult, Cystic Fibrosis genetics, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Genetic Testing methods
Abstract

Genetic testing strategies and counseling in cystic fibrosis (CF) can be problematic due to its extreme allelic heterogeneity and the difficult clinical interpretation of rare variants. Since in a previous survey of Italian CF patients, Umbria (a small region with about 900,000 inhabitants) was excluded due to the low number of chromosomes tested (<50), we have performed a comprehensive retrospective clinical and molecular survey of 62 CF patients coming from this region. We have summarized all the genotypic and phenotypic data in a table, and we interviewed the older patients in order to obtain a comprehensive overview of their conditions. We found that the c.2052&#95;2053insA (2184insA) variant, a class I mutation with high frequency in Eastern Europe but very rare in Italy, is the fourth most frequent allele in Umbria. The 2184insA variant was not included in the first-level regional screening, and we therefore suggest the implementation of this variant in the future., (© 2016 S. Karger AG, Basel.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results